Ignite Creation Date:
2025-12-25 @ 2:38 AM
Ignite Modification Date:
2026-01-05 @ 1:42 AM
Study NCT ID:
NCT03346434
Status:
COMPLETED
Last Update Posted:
2022-07-28
First Post:
2017-02-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
Sponsor:
Regeneron Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-11-30
Start Date Type:
ACTUAL
Primary Completion Date:
2021-07-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-07-08
Completion Date Type:
ACTUAL
First Submit Date:
2017-02-06
First Submit QC Date:
None
Study First Post Date:
2017-11-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-06-14
Results First Submit QC Date:
None
Results First Post Date:
2022-07-28
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-07-27
Last Update Post Date:
2022-07-28
Last Update Post Date Type:
ACTUAL